In this study, there was no difference in the detection rates of ROS1+ by ArcherDx fusion assay (0.52%, 55/9393 and WTS (0.55%, 155/28173) in the NSCLC cohort which constituted the majority of the ROS1 fusions. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.